<DOC>
	<DOCNO>NCT01712217</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy AT13387 Alone Combination Crizotinib Treatment Non-small Cell Lung Cancer .</brief_summary>
	<brief_title>A Study AT13387 Patients With Non-Small Cell Lung Cancer ( NSCLC ) Alone Combination With Crizotinib</brief_title>
	<detailed_description>This 3-part phase 1-2 study patient anaplastic lymphoma kinase ( ALK ) + potentially crizotinib-sensitive NSCLC receiving crizotinib . Part A single-arm , Phase 1 , open-label , dose escalation design patient NSCLC already receive crizotinib least 8 week continue tolerate therapy . Part B Phase 2 , open-label , randomize continuation design compare crizotinib alone versus combination crizotinib + AT13387 maximum tolerate dose establish Part A . Part C open-label , randomize , Phase 2 , Simon 's 2 stage design evaluate single agent AT13387 combination AT13387 + crizotinib MTD establish Part A patient progressed crizotinib time .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>1 . Men woman 18 year age old 2 . Must Nonsmall Cell Lung Cancer ALK+ mutation mutation rearrangement potentially sensitive crizotinib 3 . Measurable disease 4 . Must receive receive crizotinib 5 . Have adequate cardiac , bone marrow , liver kidney function 6 . Must willing able provide write informed consent comply protocol study procedures 1 . Prior anticancer treatment HSP90 inhibitor 2 . Have receive chemotherapy , radiation therapy anticancer treatment crizotinib within 3 week prior first dose study drug 3 . Prior malignancy adequately treat basal squamous cell carcinoma skin , superficial bladder cancer , lowgrade cervical cancer , nonmetastatic prostate cancer , diseasefree least 3 year 4 . Abnormal heart function 5 . Presence lifethreatening illness , medical condition , organ system dysfunction , factor 6 . Hypersensitivity AT13387 component drug product 7 . Treatment investigational drug within 3 week prior first dose study drug 8 . Severe systemic disease active uncontrolled infection 9 . Known history human immunodeficiency virus ( HIV ) seropositive test hepatitis C virus hepatitis B virus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
</DOC>